PDS Biotechnology Corporation
PDSB
$1.26
$0.021.61%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -3.75% | -17.11% | -11.40% | -5.18% | 10.31% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -29.27% | -3.24% | -31.60% | 7.17% | -44.71% |
| Operating Income | 29.27% | 3.24% | 31.60% | -7.17% | 44.71% |
| Income Before Tax | 27.03% | 1.13% | 28.93% | -9.77% | 43.05% |
| Income Tax Expenses | -- | -- | 38.18% | -- | -- |
| Earnings from Continuing Operations | 27.03% | 1.13% | 27.80% | -9.77% | 43.05% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 27.03% | 1.13% | 27.80% | -9.77% | 43.05% |
| EBIT | 29.27% | 3.24% | 31.60% | -7.17% | 44.71% |
| EBITDA | 29.32% | 3.25% | 31.64% | -7.17% | 44.75% |
| EPS Basic | 38.38% | 16.98% | 39.39% | 4.06% | 47.78% |
| Normalized Basic EPS | 38.35% | 17.00% | 40.33% | 4.08% | 47.78% |
| EPS Diluted | 38.38% | 16.98% | 39.39% | 4.06% | 48.03% |
| Normalized Diluted EPS | 38.35% | 17.00% | 40.33% | 4.08% | 47.78% |
| Average Basic Shares Outstanding | 18.40% | 19.07% | 19.13% | 14.42% | 9.04% |
| Average Diluted Shares Outstanding | 18.40% | 19.07% | 19.13% | 14.42% | 9.04% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |